IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants
1. iMDx is enrolling patients for GraftAssureDx clinical trial. 2. Ten leading transplant centers listed for the clinical trial. 3. GraftAssureDx submission to FDA expected by end of 2025. 4. Market for transplant rejection testing is valued at $1 billion. 5. Successful trial may enhance iMDx’s market positioning significantly.